Treatment of CNS TB Plus CIDP
For a patient with both CNS tuberculosis and CIDP, treat the CNS TB with rifampicin and isoniazid for 12 months, supplemented by pyrazinamide and a fourth drug (ethambutol, streptomycin, or ethionamide) for at least the first 2 months, while simultaneously managing CIDP with corticosteroids or intravenous immunoglobulin (IVIg) as first-line therapy.
CNS Tuberculosis Management
The treatment of CNS TB requires extended duration compared to pulmonary TB due to poor CNS penetration of some anti-tuberculous drugs and the high mortality/morbidity risk 1, 2.
Anti-tuberculous Regimen
- Duration: 12 months total (not the standard 6 months used for pulmonary TB)
- Initial phase (2 months minimum): Four drugs
- Rifampicin (penetrates CNS moderately)
- Isoniazid (excellent CSF penetration)
- Pyrazinamide (excellent CSF penetration)
- Fourth drug: ethambutol, streptomycin, or ethionamide 1
- Continuation phase (10 months): Rifampicin + isoniazid 2
Critical caveat: Ethambutol should be used cautiously in unconscious patients (stage III disease) since visual acuity cannot be monitored 1. If pyrazinamide cannot be tolerated, extend treatment to 18 months 1.
Adjunctive Corticosteroids for CNS TB
Corticosteroids are strongly recommended for TBM, particularly stages II and III disease 1, 2. Use dexamethasone or prednisolone (60 mg/day initially, tapering over several weeks) 1. This presents a therapeutic advantage when managing concurrent CIDP, as corticosteroids treat both conditions.
CIDP Management
CIDP requires immunomodulatory therapy, with first-line options being corticosteroids, IVIg, or plasma exchange 3, 4, 5, 6.
First-Line Treatment Options
- Corticosteroids: Effective for both CIDP and CNS TB (dual benefit in this scenario) 4, 6
- IVIg: Alternative if corticosteroids are contraindicated or ineffective 4, 6
- Plasma exchange: Consider if both IVIg and corticosteroids fail 4, 6
Maintenance Therapy
- IVIg (intravenous or subcutaneous) is recommended for maintenance 4
- Consider immunosuppressive agents if response is inadequate 4, 6
- Newer FcRn antagonists (efgartigimod) are available for refractory cases 3, 7
Integrated Treatment Strategy
Optimal Approach
Start corticosteroids as the CIDP treatment of choice since they are:
- Required for CNS TB (stages II-III meningitis) 1, 2
- Effective first-line therapy for CIDP 4, 6
- Provide dual therapeutic benefit
If Corticosteroids Are Insufficient or Contraindicated
- Add IVIg for CIDP while continuing anti-tuberculous therapy 4, 6
- Monitor for treatment response in both conditions separately
- Consider plasma exchange if both corticosteroids and IVIg fail for CIDP 4, 6
Critical Monitoring Considerations
For CNS TB
- Lumbar puncture to confirm diagnosis and monitor response
- Neuroimaging for tuberculomas or complications
- Drug susceptibility testing on M. tuberculosis isolates 8
- HIV testing (mandatory) 2
For CIDP
- Serial nerve conduction studies to document demyelination 4, 5
- Clinical disability scores
- Monitor for treatment-related adverse effects
Drug Interactions
- Rifampicin induces hepatic enzymes and may affect corticosteroid metabolism
- Adjust corticosteroid dosing as needed based on clinical response
- Pyridoxine supplementation may be needed with isoniazid, particularly if neuropathy worsens 1, 9
Important Pitfalls to Avoid
- Do not use the standard 6-month TB regimen - CNS TB requires 12 months minimum 1, 2
- Do not delay anti-tuberculous therapy - TBM is a medical emergency with high mortality if treatment is delayed 2
- Do not withhold corticosteroids - They are essential for CNS TB and beneficial for CIDP 1, 2
- Do not assume CIDP symptoms are TB-related neuropathy - These are distinct conditions requiring separate monitoring and treatment adjustments
- Monitor for paradoxical worsening - CIDP may initially worsen despite appropriate TB treatment; this requires CIDP-specific therapy intensification, not TB regimen changes